Investigating a new treatment approach for prostate cancer that resists standard therapies
Targeting a Novel Signaling Nexus pACK/pCSK/pLCK in Immune Checkpoint Blockade (ICB)-Resistant Prostate Cancer
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10876452
This study is looking at how prostate cancer can become resistant to regular treatments and is testing a new approach to help the immune system fight the cancer better by blocking a protein called ACK1, which might help improve outcomes for men with advanced prostate cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10876452 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding how prostate cancer develops resistance to standard treatments, particularly in cases known as Castration Resistant Prostate Cancer (CRPC). It explores the role of a specific protein, ACK1, in preventing immune cells from attacking the tumor. By using a new small molecule inhibitor to block ACK1, the study aims to enhance the immune response against prostate cancer. Researchers will also utilize genetically modified mice to observe how changes in ACK1 affect immune cell activation and tumor growth.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer who have developed resistance to standard hormone therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone hormone therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, particularly for patients whose cancer has become resistant to current therapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, suggesting that this approach may also be effective in prostate cancer.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAHAJAN, NUPAM P — WASHINGTON UNIVERSITY
- Study coordinator: MAHAJAN, NUPAM P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.